- Home
- AIO vs TRDA Comparison
AIO vs TRDA Comparison
Compare AIO & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIO
- TRDA
- Stock Information
- Founded
- AIO 2019
- TRDA 2016
- Country
- AIO United States
- TRDA United States
- Employees
- AIO N/A
- TRDA N/A
- Industry
- AIO Finance/Investors Services
- TRDA Biotechnology: Pharmaceutical Preparations
- Sector
- AIO Finance
- TRDA Health Care
- Exchange
- AIO Nasdaq
- TRDA Nasdaq
- Market Cap
- AIO 760.3M
- TRDA 609.7M
- IPO Year
- AIO N/A
- TRDA 2021
- Fundamental
- Price
- AIO $22.46
- TRDA $17.85
- Analyst Decision
- AIO
- TRDA Strong Buy
- Analyst Count
- AIO 0
- TRDA 3
- Target Price
- AIO N/A
- TRDA $23.33
- AVG Volume (30 Days)
- AIO 141.5K
- TRDA 132.5K
- Earning Date
- AIO 01-01-0001
- TRDA 11-05-2024
- Dividend Yield
- AIO 9.05%
- TRDA N/A
- EPS Growth
- AIO N/A
- TRDA N/A
- EPS
- AIO N/A
- TRDA 1.55
- Revenue
- AIO N/A
- TRDA $215,232,000.00
- Revenue This Year
- AIO N/A
- TRDA $47.63
- Revenue Next Year
- AIO N/A
- TRDA N/A
- P/E Ratio
- AIO N/A
- TRDA $11.51
- Revenue Growth
- AIO N/A
- TRDA 146.92
- 52 Week Low
- AIO $15.09
- TRDA $10.75
- 52 Week High
- AIO $20.25
- TRDA $20.49
- Technical
- Relative Strength Index (RSI)
- AIO 48.53
- TRDA 48.42
- Support Level
- AIO $22.00
- TRDA $19.28
- Resistance Level
- AIO $23.94
- TRDA $20.49
- Average True Range (ATR)
- AIO 0.49
- TRDA 0.92
- MACD
- AIO -0.03
- TRDA -0.01
- Stochastic Oscillator
- AIO 23.71
- TRDA 25.21
About AIO Virtus Artificial Intelligence & Technology Opportunities Fund of Beneficial Interest
Virtus Artificial Intelligence & Technology Opportunities Fund is a diversified, limited-term closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income, current gains, and long-term capital appreciation.
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.